Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.71 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.71 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delprostenate SCHEMBL8206607 | 0.92 | ABCC4 (0.84) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| SCHEMBL15389593 | 0.91 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| SCHEMBL15389592 | 0.91 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| SCHEMBL15389591 | 0.91 | PTGFR (0.78) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Froxiprost SCHEMBL563113 | 0.88 | PTGFR (0.72) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Cloprostenol SCHEMBL123596 | 0.83 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Cloprostenol SCHEMBL15669946 | 0.83 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Cloprostenol SCHEMBL14913508 | 0.83 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Cloprostenol SCHEMBL14913507 | 0.83 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1PTGER2 | |
| Cloprostenol SCHEMBL17200671 | 0.83 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113942-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2016-04-28 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2667875-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | Inceptum Research & Therapeutics, Inc. (CA) | 2013-12-04 | — | — | EP | claimed |
| US-20130309330-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2013-11-21 | — | — | US | claimed |
| WO-2012100347-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2012-08-02 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2000051617-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000051585-A2 | USE OF A NON-NATURALLY-OCCURRING EP1 SELECTIVE AGONIST FOR INCREASING BONE VOLUME | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999012551-A1 | METHOD OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
| WO-1999012550-A1 | METHOD OF INCREASING BONE VOLUME | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
| EP-0664707-B1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LAB INC (US) | 1997-06-04 | — | — | EP | claimed |
| US-5605922-A | VISION DISORDERS; SIDE EFFECT REDUCTION | ALCON LABORATORIES, INC. (US) | 1997-02-25 | — | — | US | claimed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | claimed |
| US-5480900-A | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |